Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - BIKEN/Mitsubishi Tanabe Pharma

Drug Profile

Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - BIKEN/Mitsubishi Tanabe Pharma

Alternative Names: BK 1301; DTaP vaccine - BIKEN/Mitsubishi Tanabe Pharma; Tribik

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation; Research Foundation for Microbial Diseases of Osaka University
  • Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 30 Apr 2015 Mitsubishi Tanabe Pharma files sNDA for stage 2 vaccination in prophylaxis of patients with Diphtheria, Pertusis and Tetanus in Japan (Mitsubishi Tanabe Pharma pipeline, May 2015)
  • 01 Aug 2014 Mitsubishi Tanabe Pharma completes a phase III trial in Diphtheria, Pertussis and Tetanus (Prevention, In adolescents) in Japan (NCT02118961)
  • 30 Apr 2014 Mitsubishi Tanabe Pharma in collaboration with the Research Foundation for Microbial Diseases of Osaka University initiates phase-III clinical trials in Pertussis (Prevention, In adolescents) in Japan (SC) (NCT02118961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top